We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Juventas completes phase I trial for heart failure

Juventas completes phase I trial for heart failure

April 27, 2011
CenterWatch Staff

Juventas Therapeutics, a clinical-stage regenerative medicine company that develops therapies for cardiovascular disease, has completed a phase I clinical trial evaluating the safety and preliminary efficacy of JVS-100 for treatment of patients with heart failure. 

The trial enrolled 17 New York Heart Association Class III heart failure patients, with left ventricular ejection fractions less than 40% and an average time from heart attack of 7.3 years.  Three escalating JVS-100 doses were evaluated: 5 mg (cohort 1), 15 mg (cohort 2) and 30 mg (cohort 3).  The primary safety endpoint was the number of major adverse cardiac events (MACE) at 30 days. Efficacy was assessed as changes from baseline in: echocardiographic parameters, cardiac perfusion via SPECT and clinical parameters including NYHA class, 6 minute walk distance (6MWd) and quality of life score (QOL).  Safety data has been collected for all 17-patients and 4-month efficacy data has been collected from cohort 1 and 2 patients.

The primary safety endpoint for the trial has been met with no adverse events likely related to drug.  At 4 months post-therapy, patients are demonstrating dose-dependent improvements in all clinical parameters with clinically relevant improvements compared to baseline in QOL and 6MWd for patients from cohort 2.  At 1-month after dosing in cohort 3 patients are showing similar clinically relevant improvements in QOL and 6MWd with some patients improving a full New York Heart Association class.

 

United States Clinical Intelligence

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing